Zolbetuximab
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Zolbetuximab
- DrugBank Accession Number
- DB15118
- Background
Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
- Zolbetuximab
- External IDs
- IMAB 362
- IMAB-362
- IMAB362
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Zolbetuximab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Zolbetuximab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Zolbetuximab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zolbetuximab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Zolbetuximab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TF5MPQ8WGY
- CAS number
- 1496553-00-4
References
- General References
- Not Available
- External Links
- Wikipedia
- Zolbetuximab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer / Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer / Metastatic Gastric Adenocarcinoma or Cancer / Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma 2 2 Completed Treatment CLDN18.2-positive Adenocarcinoma of Esophagus / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction / CLDN18.2-positive Gastric Adenocarcinoma 1 2 Completed Treatment Solid Tumors 1 2 Recruiting Treatment Gastric Cancer / Gastroesophageal Junction Cancer / Pharmacokinetics of Fluorouracil Bolus (5-FU) / Pharmacokinetics of Oxaliplatin / Pharmacokinetics of Zolbetuximab 1 2 Recruiting Treatment Pancreatic Adenocarcinoma Metastatic / Pancreatic Cancer / Pancreatic Metastatic Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:51 / Updated at July 18, 2023 22:57